Molecular Formula | C20H21NO3S |
Molar Mass | 355.45064 |
Melting Point | >120°C (dec.) |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Appearance | Solid |
Color | Off-White to Pale Yellow |
Storage Condition | Hygroscopic, Refrigerator, Under Inert Atmosphere |
Stability | Hygroscopic |
overview | prasugrel hydrochloride (Prasugrel) is an oral antiplatelet drug jointly developed by Eli Lilly and its first pharmaceutical company. it was approved for listing in the European union and the United States in 2009. It is used to reduce thrombotic cardiovascular events (including in-stent thrombosis) in patients with acute coronary syndrome who will receive percutaneous coronary intervention. Prasugrel, chemical name: 5-[(1RS)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6, 7-tetrahydrothieno [3,2-c] pyridine-2-acetate. The synthetic route of prasugrel in the existing technology is mainly the original synthetic route of Japan's Sankyo company, using o-fluorobromobenzyl as the starting material, making it into a format reagent and condensing it with cyclonitrile to obtain 1-cyclopropyl -2-(2-fluorophenyl) ethanone, and then bromating it at the α position, and then substituting it with 2-thiophene and pyridine, the obtained product is acetylated to obtain prasugrel. In the process of synthesis according to the above process, a new unknown impurity without fluorine prasugrel was found in one of the batch of pilot scale-up prasugrel raw material detection patterns, which is not an intermediate of the above reaction. Therefore, it is necessary to study the new impurities of prasugrel. |